| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Internal
Medicine,
Glucagon-like peptide-1-(7
36) amide
(GLP-1) is an incretin hormone of the enteroinsular axis. Recent
experimental evidence in animals and healthy subjects suggests that
GLP-1 has a role in controlling appetite and energy intake in humans.
We have therefore examined in a double-blind, placebo-controlled,
crossover study in 12 patients with diabetes type 2 the effect of
intravenously infused GLP-1 on appetite sensations and energy intake.
On 2 days, either saline or GLP-1 (1.5 pmol · kg
1 · min1)
was given throughout the experiment. Visual analog scales were used to
assess appetite sensations; furthermore, food and fluid intake of a
test meal were recorded, and blood was sampled for analysis of plasma
glucose and hormone levels. GLP-1 infusion enhanced satiety and
fullness compared with placebo (P = 0.028 for fullness and P = 0.026 for
hunger feelings). Energy intake was reduced by 27% by GLP-1
(P = 0.034) compared with saline. The
results demonstrate a marked effect of GLP-1 on appetite by showing
enhanced satiety and reduced energy intake in patients with diabetes
type 2.
appetite; brain-gut peptides; obesity
This article has been cited by other articles:
|
|
 |
|
  J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Degen, J. Drewe, F. Piccoli, K. Grani, S. Oesch, R. Bunea, M. D'Amato, and C. Beglinger Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1391 - R1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Gutzwiller, L. Degen, D. Matzinger, S. Prestin, and C. Beglinger Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R562 - R567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vrang, C. B. Phifer, M. M. Corkern, and H.-R. Berthoud Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R470 - R478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Egan, G. S. Meneilly, and D. Elahi Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1072 - E1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. MacDonald, W. El-kholy, M. J. Riedel, A. M. F. Salapatek, P. E. Light, and M. B. Wheeler The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion Diabetes, December 1, 2002; 51(90003): S434 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Elbrond, G. Jakobsen, S. Larsen, H. Agerso, L. B. Jensen, P. Rolan, J. Sturis, V. Hatorp, and M. Zdravkovic Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects Diabetes Care, August 1, 2002; 25(8): 1398 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. I Steinle, W.-C. Hsueh, S. Snitker, T. I Pollin, H. Sakul, P. L St Jean, C. J Bell, B. D Mitchell, and A. R Shuldiner Eating behavior in the Old Order Amish: heritability analysis and a genome-wide linkage analysis Am. J. Clinical Nutrition, June 1, 2002; 75(6): 1098 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Schirra, U Wank, R Arnold, B Goke, and M Katschinski Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans Gut, March 1, 2002; 50(3): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agerso, J. Veldhuis, N. Porksen, and O. Schmitz Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes Diabetes, February 1, 2002; 51(2): 424 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Larsen, C. Fledelius, L. B. Knudsen, and M. Tang-Christensen Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats Diabetes, November 1, 2001; 50(11): 2530 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Peters, Y.-H. Choi, P. L. Brubaker, and G. H. Anderson A Glucagon-Like Peptide-1 Receptor Agonist and an Antagonist Modify Macronutrient Selection by Rats J. Nutr., August 1, 2001; 131(8): 2164 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Beglinger, L. Degen, D. Matzinger, M. D'Amato, and J. Drewe Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2001; 280(4): R1149 - R1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Baggio, F. Adatia, T. Bock, P. L. Brubaker, and D. J. Drucker Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, beta -Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice J. Biol. Chem., October 27, 2000; 275(44): 34471 - 34477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lovshin, J. Estall, B. Yusta, T. J. Brown, and D. J. Drucker Glucagon-like Peptide (GLP)-2 Action in the Murine Central Nervous System Is Enhanced by Elimination of GLP-1 Receptor Signaling J. Biol. Chem., June 8, 2001; 276(24): 21489 - 21499. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
